Author

Anju Singh

University of Alabama at BirminghamORCID 0000-0002-2364-2925Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Adam B. KeetoniD· 1 shared Asfar Sohail AzmiiD· 1 shared Bassel F. El‐RayesiD· 1 shared Craig M. PowelliD· 1 shared Dhana Sekhar Reddy BandiiD· 1 shared Donald J. BuchsbaumiD· 1 shared Elmar NurmemmedoviD· 1 shared Ganji Purnachandra NagarajuiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Adam B. KeetonORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma

Dhana Sekhar Reddy Bandi, Ganji Purnachandra Nagaraju, Sujith Sarvesh, J. -W. Wang, Jeremy B. Foote, Adam B. Keeton, Xi Chen, Verónica Ramírez‐Alcántara, Thomas Holmes, Mehmet Akce, Anju Singh, Craig M. Powell, Santosh Kumar Behera, Asfar Sohail Azmi, Elmar Nurmemmedov, , Bassel F. El‐Rayes

Oral PDE10 inhibitor ADT-030 curbed KRAS-mutant pancreatic cancer growth and metastasis in mouse models, stayed active in KRAS-inhibitor-resistant cells, and shifted tumor immune profiles.

bioRxiv · Sep 3, 2026 · PreprintCancer Biology✦ In-depth digest